Noor F. Al-Assaf

Dr. Noor F. Al-Assaf

School of Medicine, The University of Jordan, Amman, Al ‘Āşimah, Jordan
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2025 in Children
Verified
Journal Article
Open access
PDF file
Fareed Khdair AhmadFareed Khdair Ahmad
Fareed Khdair Ahmad
NANoor F. Al-Assaf
Noor F. Al-Assaf
MAMohammad Alzoubi
Mohammad Alzoubi
NONada Odeh
Nada Odeh
DSDina Samara
Dina Samara
Yaser M. RayyanYaser M. Rayyan
Yaser M. Rayyan
Background/Objectives: Gastrostomy tube (GT) placement plays a vital role in managing children with chronic illnesses who are unable to meet their nutritional needs orally. While its clinical benefits are well established, limited data exist on caregivers’ satisfaction with GT use in Jordan. This study aimed to assess caregivers’ satisfaction and identify factors that influence their experiences by using a validated satisfaction scoring system in which a score greater than 20 indicates a high level of satisfaction. Methods: A cross-sectional study was conducted at Jordan University Hospital, including children under 18 years of age who underwent endoscopic GT insertion between July 2017 and December 2024. Caregivers completed the Structured Satisfaction Questionnaire with Gastrostomy Feeding (SAGA-8), and demographic and clinical data were collected. Statistical analyses explored associations between satisfaction levels and patient-, caregiver-, and healthcare-related factors. Results: A total of 46 caregivers participated. The median satisfaction score was 26.1, surpassing the high satisfaction threshold of 20. Overall, 63% of caregivers expressed satisfaction or high satisfaction with GT feeding, and 82.6% were satisfied with the support provided by the healthcare team. Additionally, 69.5% and 65.2% of caregivers reported improvements in their child’s nutritional status and overall family well-being, respectively. Notably, 89.1% observed a reduction in feeding time, and 84.8% reported fewer respiratory infections following GT placement. Over half of the caregivers (58.7%) indicated that they would have agreed to earlier GT placement if they had been more aware of its benefits. Conclusions: Caregivers reported high satisfaction with GT use, with scores well above the validated threshold indicating high satisfaction. These findings highlight the positive impact of GT placement on children’s health outcomes and family quality of life. Enhancing caregiver education and providing robust healthcare support are crucial to improving the management of children who require GT feeding.

18 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HHHadeel Halalsheh
Hadeel Halalsheh
NONada Odeh
Nada Odeh
AKArwa Kiswani
Arwa Kiswani
MAMohammad Alzoubi
Mohammad Alzoubi
ADAdam Diab
Adam Diab
ISIyad Sultan
Iyad Sultan
Background: Accurate staging is vital for optimizing outcomes in pediatric rhabdomyosarcoma (RMS). While [18F]-FDG PET/CT is increasingly utilized, its specific impact on clinical management and its prognostic value compared to conventional imaging (CI) require further evaluation. Methods: In this retrospective single-center study, we reviewed 56 pediatric patients with RMS who underwent [18F]-FDG PET/CT at our center. Imaging findings were compared with CI (CT/MRI) and correlated with clinical management and survival outcomes. Results: In the total cohort (n = 56), PET/CT demonstrated high concordance with CI for nodal assessment, with an apparent sensitivity of 89.5% and specificity of 94.6%. PET/CT identified skeletal metastases in 5 patients (8.9%) and correctly characterized suspicious pulmonary nodules in one case, though it failed to detect a 0.6 cm lung nodule visualized on chest CT. Notably, PET/CT findings directly altered clinical management in 16.1% of patients (n = 9), primarily through radiotherapy adjustments, including field expansions (n = 4), field reductions (n = 3), and the initiation of previously unplanned radiotherapy (n = 2). At a median follow-up of 33.3 months, an exploratory analysis showed that patients with an SUVmax ≥3.6 had a lower 3-year EFS (57.6% vs. 71.6%; p = 0.51) and OS (60.4% vs. 71.6%; p = 0.63); neither comparison reached statistical significance. Conclusion: [18F]-FDG PET/CT is a powerful adjunct in pediatric RMS staging, particularly for nodal and skeletal evaluation. Its ability to refine radiotherapy planning in nearly one-sixth of cases underscores its clinical utility. SUVmax is not a validated prognostic or predictive biomarker in pediatric RMS; prospective, adequately powered multicenter studies, ideally incorporating volumetric PET parameters, are needed before any role in risk-stratified therapy can be defined.

8 September 2025 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
MAMohammad Alzoubi
Mohammad Alzoubi
ADAdam Diab
Adam Diab
NONada Odeh
Nada Odeh
NANoor F. Al-Assaf
Noor F. Al-Assaf
SAShrouq Amer
Shrouq Amer
HHHadeel Halalsheh
Hadeel Halalsheh
Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2. Methods: We reviewed retrospectively children younger than 2 years with newly diagnosed RMS treated from January 2002 until December 2022 at King Hussein Cancer Center. Demographics, clinical characteristics, and outcomes were analyzed. Statistical analysis included descriptive statistics and survival analysis using Kaplan-Meier methods. All cases were reviewed in a multidisciplinary clinic comprising experienced radiotherapists and surgeons. Results: We identified 34 cases of RMS in patients younger than 2 years at diagnosis. The median age was 13 months, with 70.6% males. The most common tumor site was bladder/prostate (N=13, 38%), followed by orbit (N=5, 14.7%), the predominant subtype was embryonal (N=30). Risk-stratification categorized 17.6% as low-risk and 79.4% as intermediate-risk. Twenty-five patients had tumors >5 cm, with metastasis in 6 (17.6%). All patients received neo-adjuvant chemotherapy, local control was by radiotherapy only (n=12, 35.3%), combined surgery and radiotherapy (n=11, 32.4%), or surgery alone (n=3, 8.8%). The 5-year event-free and overall survival rates were 55.1% and 57.5%, respectively. Fourteen patients experienced relapse/progression, with local relapse the most common pattern. TNM stage, clinical group, metastasis at diagnosis, and radiotherapy use significantly impacted survival. Conclusions: Children under 2 years of age with RMS face significant challenges, with high local recurrence rates and suboptimal survival outcomes compared with older pediatric patients. Our findings highlight the need for tailored treatment approaches that balance effective local control with minimizing long-term toxicity.

10 April 2026 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
Yaser M. RayyanYaser M. Rayyan
Yaser M. Rayyan
NONada Odeh
Nada Odeh
LTLaith Theeb
Laith Theeb
YAYazeed Y. Alajlouni
Yazeed Y. Alajlouni
MAMohammad Alzoubi
Mohammad Alzoubi
AAAhmad M. Alhaj
Ahmad M. Alhaj
Introduction: Gastrointestinal (GI) malignancies are a major cause of cancer-related morbidity and mortality. While prognostic tools such as TNM staging and serum biomarkers are widely used, they have limitations. The C-reactive protein-albumin-lymphocyte (CALLY) index, an integrated marker of inflammation, nutrition, and immunity, has emerged as a potential prognostic tool. However, its prognostic value across GI malignancies remains unclear. This systematic review aims to assess the prognostic significance of the CALLY index in GI malignancies, with a primary focus on survival outcomes and a secondary assessment of its association with postoperative complications. Methodology: Relevant literature was screened through December 2024 to identify studies assessing the prognostic significance of the CALLY index in GI malignancies. Outcomes included overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), recurrence-free survival (RFS), recurrence rates, and postoperative complications. Eligible studies underwent qualitative synthesis, while meta-analysis was conducted for gastric cancer only. Relative risks (RRs) were pooled using a fixed- or random-effects model based on heterogeneity (I² > 50%). Subgroup analyses were performed based on CALLY cutoff values and TNM stage. Publication bias was assessed using funnel plots and Egger’s test. Results: A total of 21 studies (8,600 patients) met inclusion criteria. Across all GI malignancies, higher CALLY values, regardless of cutoff variations (range: 0.369–6.96), were consistently associated with improved OS, CSS, DFS, and RFS, while lower values correlated with increased recurrence rates and higher postoperative complication rates. In gastric cancer, a higher CALLY index was associated with improved 5-year OS (RR = 0.81, p < 0.00001) and lower major postoperative complications (RR = 1.48, p = 0.02). Subgroup analysis suggested that a CALLY cutoff < 3 and TNM stage IV inclusion contributed to heterogeneity. No significant publication bias was detected. Conclusion: The CALLY index appears to be a promising independent prognostic biomarker in GI malignancies, with higher values associated with improved survival and fewer postoperative complications. In gastric cancer specifically, meta-analysis confirms its predictive value for 5-year overall survival and major postoperative outcomes. Larger prospective studies are warranted to establish standardized cutoff points and to optimize its clinical utility across diverse patient populations.

7 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HHHadeel Halalsheh
Hadeel Halalsheh
LALana Amer
Lana Amer
MAMohammad Alzoubi
Mohammad Alzoubi
NANoor F. Al-Assaf
Noor F. Al-Assaf
ADAdam Diab
Adam Diab
ISIyad Sultan
Iyad Sultan
Background: Systemic inflammation has been implicated in prognosis of multiple malignancies, yet evidence regarding its role in Wilms Tumor (WT) remains scarce. We investigated the prognostic significance of pre-treatment inflammatory markers in unilateral WT. Methods: We conducted a retrospective analysis of children with unilateral WT treated at our institution between November 2014 and December 2023. Clinical characteristics, treatment, and outcomes were evaluated. Inflammatory markers included a novel pan-immune-inflammation value (PIV), neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR). Optimal cut-off values for Event-Free Survival (EFS) and Overall survival (OS) were determined using data-derived optimization to maximize survival curve separation (surv_cutpoint). Cox proportional hazards models were used for survival analysis, while ROC curves were used to calculate AUC values and confirm optimal cut-off points. Results: We included 91 patients (median age: 3.6 years; 62% female), of whom 34% presented with metastasis. Higher EFS was significantly associated with low PIV (cut-off 288.9), low NLR (cut-off 1.1), and high LMR (cut-off 6.3). Similarly, OS was positively associated with lower PIV (HR 8.56 for high PIV, p = 0.038) and lower NLR (HR 4.63 for high NLR, p = 0.043). ROC analysis confirmed their discriminative ability; when evaluated at the unified survival cutpoints, LMR yielded an AUC of 0.692 for 5-year mortality (at cut-off 6.3), while NLR yielded an AUC of 0.671 for 5-year events (at cut-off 1.1). Conclusions: Pre-treatment inflammatory markers demonstrate significant prognostic value in unilateral WT. Elevated NLR and PIV, along with lower LMR, correlate with poorer survival. These accessible biomarkers provide a valuable, low-cost tool for risk assessment. Our optimal thresholds differed from Western adult cohorts, emphasizing the need for population-specific reference intervals in global pediatric oncology.